litlas
ログインアカウント作成

Ronald de Wit

1988–2025 年に発表

130
論文数
36,715
被引用数
86
h 指数
130
i10 指数

被引用数

Ronald de Wit の年別被引用数1896 年: 被引用 2 件1989 年: 被引用 2 件1990 年: 被引用 3 件1991 年: 被引用 5 件1992 年: 被引用 3 件1993 年: 被引用 2 件1994 年: 被引用 2 件1997 年: 被引用 4 件1998 年: 被引用 10 件1999 年: 被引用 9 件2000 年: 被引用 13 件2001 年: 被引用 24 件2002 年: 被引用 24 件2003 年: 被引用 35 件2004 年: 被引用 56 件2005 年: 被引用 116 件2006 年: 被引用 116 件2007 年: 被引用 110 件2008 年: 被引用 164 件2009 年: 被引用 168 件2010 年: 被引用 193 件2011 年: 被引用 159 件2012 年: 被引用 170 件2013 年: 被引用 304 件2014 年: 被引用 250 件2015 年: 被引用 254 件2016 年: 被引用 282 件2017 年: 被引用 270 件2018 年: 被引用 338 件2019 年: 被引用 1,076 件2020 年: 被引用 1,222 件2021 年: 被引用 1,253 件2022 年: 被引用 927 件2023 年: 被引用 628 件2024 年: 被引用 1,054 件2025 年: 被引用 447 件2026 年: 被引用 8 件1897〜1988 年は被引用が無いため表示していません1995〜1996 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,229 件、この内訳の 24.5%中国: 引用元論文 973 件、この内訳の 7.4%イギリス: 引用元論文 924 件、この内訳の 7%イタリア: 引用元論文 739 件、この内訳の 5.6%ドイツ: 引用元論文 730 件、この内訳の 5.5%カナダ: 引用元論文 698 件、この内訳の 5.3%フランス: 引用元論文 648 件、この内訳の 4.9%オランダ: 引用元論文 511 件、この内訳の 3.9%日本: 引用元論文 491 件、この内訳の 3.7%スペイン: 引用元論文 456 件、この内訳の 3.4%スイス: 引用元論文 335 件、この内訳の 2.5%オーストラリア: 引用元論文 325 件、この内訳の 2.5%
0%24.5%その他 23.8%

機関

分野

  • Medicine81.9%
  • Biochemistry, Genetics and Molecular Biology11.3%
  • Immunology and Microbiology2.9%
  • Engineering0.9%
  • Materials Science0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • その他1.8%

トピック

  • Prostate Cancer Treatment and Research12.2%
  • Cancer Immunotherapy and Biomarkers7.6%
  • Bladder and Urothelial Cancer Treatments5.9%
  • Prostate Cancer Diagnosis and Treatment5.2%
  • Radiopharmaceutical Chemistry and Applications3.1%
  • Urinary and Genital Oncology Studies2.8%
  • その他63.2%

共著者

全論文

検索で開く
  1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    著者: Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin - New England Journal of Medicine 2017 被引用: 3,390

  2. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    著者: Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono - New England Journal of Medicine 2012 被引用: 4,574

  3. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

    著者: Ian F. Tannock, Ronald de Wit, William R. Berry, J Horti, A Płużańska, Kim N., Stéphane Oudard, Christine Théodore, Nicholas D. James, Ingela Turesson, Mark Rosenthal, Mario A. Eisenberger - New England Journal of Medicine 2004 被引用: 5,725

  4. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

    著者: Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, Jeffrey C. Goh, Kristiina Ojamaa, Christopher Hoimes, Ulka N. Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko, Ronald de Wit, Chunde Li, Aurelius Omlin, Giuseppe Procopio, Satoshi Fukasawa, Ken-ichi Tabata, Se Hoon Park, Susan Feyerabend, Charles G. Drake, Haiyan Wu, Ping Qiu, Jeri Kim, Christian Poehlein, Johann S. de Bono - Journal of Clinical Oncology 2019 被引用: 706

  5. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

    著者: Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward Uchio, Joost L. Boormans, M. Roumiguié, Laurence E. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Haojie Li, Kijoeng Nam, Ekta Kapadia, Tara L. Frenkl, Ronald de Wit - The Lancet Oncology 2021 被引用: 533

  6. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

    著者: Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R. Plimack, Noah M. Hahn, Ronald de Wit, Lei Pang, Mary J. Savage, Rodolfo F. Perini, Stephen J. O’Keefe, Dean F. Bajorin, Joaquim Bellmunt - The Lancet Oncology 2017 被引用: 1,342

  7. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

    著者: Ronald de Wit, Johann S. de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean‐Christophe Eymard, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Théodore, Susan Feyerabend, Carole Hélissey, Ayse Ӧzatılgan, Christine Geffriaud-Ricouard, Daniel Castellano - New England Journal of Medicine 2019 被引用: 660

  8. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

    著者: Yves Fradet, Joaquim Bellmunt, David J. Vaughn, J L Lee, Lawrence Fong, Nicholas J. Vogelzang, M.Á. Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, K. Nam, Tara L. Frenkl, Rodolfo F. Perini, Ronald de Wit, Dean F. Bajorin - Annals of Oncology 2019 被引用: 488

  9. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

    著者: Maria De Santis, Joaquim Bellmunt, Graham M. Mead, J. Martijn Kerst, Michael Leahy, Pablo Maroto, Thierry Gil, Sandrine Marréaud, Gedske Daugaard, Iwona Skoneczna, Sandra Collette, Julie Lorent, Ronald de Wit, Richard Sylvester - Journal of Clinical Oncology 2011 被引用: 773

  10. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

    著者: Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell, Petros Grivas, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Noah M. Hahn, Mary J. Savage, Xiao Fang, James Luke Godwin, Tara L. Frenkl, Blanca Homet Moreno, Ronald de Wit, Elizabeth R. Plimack - Journal of Clinical Oncology 2020 被引用: 292

  11. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

    著者: Arjun Vasant Balar, Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky, Yves Fradet, Jia-Lin Lee, Lawrence Fong, Nicholas J. Vogelzang, José A. Martínez-Climent, Andrea Necchi, Daniel P. Petrylak, Elizabeth R. Plimack, Jin Xu, Kazuo Imai, Blanca Homet Moreno, Joaquim Bellmunt, Ronald de Wit, Peter H. O’Donnell - Annals of Oncology 2022 被引用: 114

  12. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

    著者: Lisanne F. van Dessel, Job van Riet, Minke Smits, Yanyun Zhu, Paul Hamberg, Michiel S. van der Heijden, Andries M. Bergman, Inge M. van Oort, Ronald de Wit, Emile E. Voest, Neeltje Steeghs, Takafumi N. Yamaguchi, Julie Livingstone, Paul C. Boutros, John W.M. Martens, Stefan Sleijfer, Edwin Cuppen, Wilbert Zwart, Harmen J.G. van de Werken, Niven Mehra, Martijn P. Lolkema - Nature Communications 2019 被引用: 209

  13. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

    著者: Silke Gillessen, Nicolas Sauvé, Laurence Collette, Gedske Daugaard, Ronald de Wit, Costantine Albany, A. Tryakin, Karim Fizazi, Olof Ståhl, Jourik A. Gietema, Ugo De Giorgi, Fay Cafferty, Aaron R. Hansen, Torgrim Tandstad, Robert Huddart, Andrea Necchi, Christopher J. Sweeney, Xavier García del Muro, Daniel Yick Chin Heng, Anja Lorch, Michal Chovanec, Eric Winquist, Peter Grimison, Darren R. Feldman, Angelika Terbuch, Marcus Hentrich, Carsten Bokemeyer, Helene F. S. Negaard, Christian D. Fankhauser, Jonathan Shamash, David J. Vaughn, Cora N. Sternberg, Axel Heidenreich, J. Beyer - Journal of Clinical Oncology 2021 被引用: 238

  14. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

    著者: Dominik Berthold, Gregory R. Pond, Freidele Soban, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock - Journal of Clinical Oncology 2008 被引用: 1,145

  15. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

    著者: Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg, Sylvestre Le Moulec, Stéphane Oudard, Ugo De Giorgi, Michael Krainer, Andries M. Bergman, Wolfgang Hoelzer, Ronald de Wit, Martin Bögemann, Fred Saad, Giorgio Cruciani, Antoine Thiery-Vuillemin, Susan Feyerabend, Kurt Miller, Nadine Houédé, Syed A. Hussain, Elaine T. Lam, Jonathan Polikoff, Arnulf Stenzl, Paul N. Mainwaring, David A. Ramies, Colin Hessel, Aaron Weitzman, Karim Fizazi - Journal of Clinical Oncology 2016 被引用: 247

  16. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

    著者: Glenn Heller, Robert McCormack, Thian Kheoh, Arturo Molina, Matthew R. Smith, Robert Dreicer, Fred Saad, Ronald de Wit, Dana T. Aftab, Mohammad Hirmand, Ana Limon, Karim Fizazi, Martin Fleisher, Johann S. de Bono, Howard I. Scher - Journal of Clinical Oncology 2017 被引用: 230

  17. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

    著者: Andrea Necchi, M. Roumiguié, Ashish M. Kamat, Neal D. Shore, Joost L. Boormans, Adil Esen, Thierry Lebrét, Shuya Kandori, Dean F. Bajorin, Laurence E. Krieger, Scot A. Niglio, Edward Uchio, Ho Kyung Seo, Ronald de Wit, Eric A. Singer, Petros Grivas, Hiroyuki Nishiyama, Haojie Li, Pranshu Baranwal, Margot Van den Sigtenhorst-Fijlstra, Ekta Kapadia, Girish S. Kulkarni - The Lancet Oncology 2024 被引用: 85

  18. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

    著者: Cora N. Sternberg, Iwona Skoneczna, J. Martijn Kerst, Peter Albers, Sophie D. Fosså, Mads Agerbæk, Herlinde Dumez, Maria De Santis, Christine Théodore, Michael Leahy, John Chester, A. Verbaeys, Gedske Daugaard, Lori Wood, J. Alfred Witjes, Ronald de Wit, L. Geoffrois, Lisa Sengeløv, George N. Thalmann, Danielle Charpentier, Frédéric Rolland, L. Mignot, Santhanam Sundar, Paul Symonds, John D. Graham, Florence Joly, Sandrine Marréaud, Laurence Collette, Richard Sylvester - The Lancet Oncology 2014 被引用: 387

  19. The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer

    著者: Gregory R. Pond, Guru Sonpavde, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, Andrew J. Armstrong - European Urology 2013 被引用: 198

  20. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

    著者: J. Beyer, Laurence Collette, Nicolas Sauvé, Gedske Daugaard, Darren R. Feldman, Torgrim Tandstad, A. Tryakin, Olof Ståhl, Enrique González‐Billalabeitia, Ugo De Giorgi, Stéphane Culine, Ronald de Wit, Aaron R. Hansen, Marko Bebek, Angelika Terbuch, Costantine Albany, Marcus Hentrich, Jourik A. Gietema, Helene F. S. Negaard, Robert Huddart, Anja Lorch, Fay Cafferty, Daniel Yick Chin Heng, Christopher J. Sweeney, Eric Winquist, Michal Chovanec, Christian D. Fankhauser, Dan Stark, Peter Grimison, Andrea Necchi, Ben Tran, Axel Heidenreich, Jonathan Shamash, Cora N. Sternberg, David J. Vaughn, Ignacio Durán, Carsten Bokemeyer, Anna Patrikidou, Richard Cathomas, Samson Yaekob Assele, Silke Gillessen - Journal of Clinical Oncology 2021 被引用: 171

  21. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells

    著者: Lisanne Mout, Lisanne F. van Dessel, Jaco Kraan, Anouk C. de Jong, Rui P. Neves, Sigrun Erkens‐Schulze, Corine M. Beaufort, Anieta M. Sieuwerts, Job van Riet, Thomas Woo, Ronald de Wit, Stefan Sleijfer, Paul Hamberg, Yorick Sandberg, Peter A.W. te Boekhorst, Harmen J.G. van de Werken, John W.M. Martens, Nikolas H. Stoecklein, Wytske M. van Weerden, Martijn P. Lolkema - European Journal of Cancer 2021 被引用: 92

  22. Cross-resistance and drug sequence in prostate cancer

    著者: Stefan A.J. Buck, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ronald de Wit, Robert J. van Soest - Drug Resistance Updates 2021 被引用: 82

  23. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

    著者: Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas - Clinical Cancer Research 2022 被引用: 48

  24. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

    著者: Felix E. de Jongh, Ruben N. van Veen, S J Veltman, Ronald de Wit, M.E.L. van der Burg, Martin J. van den Bent, A.S.T. Planting, Wilfried J. Graveland, G. Stoter, Jaap Verweij - British Journal of Cancer 2003 被引用: 267